Last reviewed · How we verify
NESP
NESP is a recombinant human erythropoietin analog that stimulates erythropoiesis.
NESP is a recombinant human erythropoietin analog that stimulates erythropoiesis. Used for Chronic kidney disease-related anemia.
At a glance
| Generic name | NESP |
|---|---|
| Also known as | Aranesp, Darbepoetin alfa |
| Sponsor | Genexine, Inc. |
| Drug class | erythropoiesis-stimulating agent |
| Target | erythropoietin receptor |
| Modality | Small molecule |
| Therapeutic area | Nephrology |
| Phase | Phase 3 |
Mechanism of action
NESP works by mimicking the action of endogenous erythropoietin, a hormone that regulates red blood cell production. This leads to an increase in red blood cell mass and hemoglobin levels, which can help alleviate anemia in patients with chronic kidney disease.
Approved indications
- Chronic kidney disease-related anemia
Common side effects
- Hypertension
- Headache
- Nausea
- Fatigue
- Dizziness
Key clinical trials
- Setmelanotide to Treat Obesity in a Patient With Pseudohypoparathyroidism Type 1a (PHP1a) (PHASE2)
- Luspatercept + Darbepoetin in MDS (PHASE2)
- Vafseo Outcomes In-Center Experience (PHASE3)
- Choices About Genetic Testing And Learning Your Risk With Smart Technology (NA)
- Darbe Plus IV Iron to Decrease Transfusions While Maintaining Iron Sufficiency in Preterm Infants (PHASE2)
- Efficacy and Safety Study to Evaluate MT-6548 in Non-dialysis Subjects With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- Efficacy and Safety Study to Evaluate MT-6548 in Hemodialysis Subjects Currently Receiving ESAs With Anemia Associated With Chronic Kidney Disease in Japan (PHASE3)
- A Study to Evaluate Efficacy and Safety of QLG1218(Daprodustat) in Chinese Hemodialysis (HD)-Dependent Subjects With Anemia Associated With Chronic Kidney Disease (CKD) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- NESP CI brief — competitive landscape report
- NESP updates RSS · CI watch RSS
- Genexine, Inc. portfolio CI